Non-canonical AR activity facilitates endocrine resistance in breast cancer

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome

(2018) Carmela Ricciardelli et al.   CLINICAL CANCER RESEARCH

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

(2017) Rinath Jeselsohn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer

(2016) A. Thakkar et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy

(2016) Miho Kono et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis

(2016) Mohammad A. Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance

(2016) Jelani C. Zarif et al.   CELLULAR SIGNALLING

Cooperative Dynamics of AR and ER Activity in Breast Cancer

(2016) N. C. D'Amato et al.   MOLECULAR CANCER RESEARCH

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

(2015) J. O'Shaughnessy et al.   ANNALS OF ONCOLOGY

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer

(2015) Andrew Ciupek et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival

(2015) Beth Overmoyer et al.   CANCER RESEARCH

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

(2015) Ana Bosch et al.   Science Translational Medicine

Targeting the Androgen Receptor in Breast Cancer

(2015) KeeMing Chia et al.   Current Oncology Reports

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

(2015) Anu-Maarit Moilanen et al.   Scientific Reports

A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer

(2015) Kee Ming Chia et al.   NEOPLASIA

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

(2014) Yassine Rechoum et al.   BREAST CANCER RESEARCH AND TREATMENT

Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer

(2014) S. T. Bailey et al.   CANCER RESEARCH

Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma

(2014) Rika Fujii et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells

(2014) Wei-Min Chung et al.   Stem Cell Research

Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/EnzalutamideversusAnti-androgen Receptor ASC-J9® Lead to PromotionversusSuppression of Prostate Cancer Metastasis

(2013) Tzu-Hua Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

(2012) T. E. Hickey et al.   MOLECULAR ENDOCRINOLOGY

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

(2012) Caryn S. Ross-Innes et al.   NATURE

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer

(2011) Min Ni et al.   CANCER CELL

FOXA1: master of steroid receptor function in cancer

(2011) Michael A Augello et al.   EMBO JOURNAL

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1

(2011) Jessica L L Robinson et al.   EMBO JOURNAL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers

(2011) Y Wang et al.   ONCOGENE

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

(2011) M. J. Evans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

(2011) S. R. Oakes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FOXA1 is a key determinant of estrogen receptor function and endocrine response

(2010) Antoni Hurtado et al.   NATURE GENETICS

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers

(2010) Donata Micello et al.   VIRCHOWS ARCHIV

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Androgen Receptor Inhibits Estrogen Receptor-  Activity and Is Prognostic in Breast Cancer

(2009) A. A. Peters et al.   CANCER RESEARCH

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

(2009) Leo A Niemeier et al.   MODERN PATHOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE